Risk factors for depressive symptoms in glaucoma patients: a nationwide case-control study.
Su Chien-Chia, Chen Judy Yi-Chu, Wang Tsing-Hong, Huang Jehn-Yu, Yang Chung-May, Wang I-Jong
AI Summary
This study found that in glaucoma patients, higher comorbidity burden, particularly with systemic beta-blockers and calcium channel blockers, significantly increases depression risk, not topical glaucoma medications.
Abstract
Purpose
The purpose was to investigate the risk factors for depressive symptoms in glaucoma patients.
Methods
From the Longitudinal Health Insurance Database in Taiwan, we included 1190 glaucoma patients with subsequent depression diagnoses in the case group and randomly selected 4673 glaucoma patients without depression diagnoses as the control group, matched by age, sex, and time of glaucoma diagnosis. The age-adjusted Charlson comorbidity index (ACCI) score was used to compute the burden of comorbidity for each patient. Current use (past 6 months) of topical antiglaucoma medications and systemic medications was identified. Multivariate regression was used to analyze the risk factors for depression.
Results
The mean age for glaucoma patients was 61.88 years. Patients with depressive symptoms had significantly higher ACCI scores (P < .0001). The current use of any topical antiglaucoma medications was not associated with an increased risk for depression. However, higher ACCI scores (P < .0001), cerebrovascular diseases (odds ratio [OR] = 1.324, 95 % confidence interval [CI] = 1.118--1.568), dementia (OR = 2.647, 95 % CI = 2.142-3.270), thyroid diseases (OR = 1.720, 95 % CI = 1.366-2.165), headaches (OR = 1.299, 95 % CI = 1.112-1.518), and current use of systemic β-blockers (OR = 1.782, 95 % CI = 1.538-2.065) and calcium channel blockers (OR = 1.396, 95 % CI, 1.197-1.629) were found to increase the risk of depression in glaucoma patients.
Conclusions
In this study, a comorbidity burden was a significant risk factor for depression in glaucoma patients, particularly for those currently using systemic β-blockers and calcium channel blockers.
MeSH Terms
Shields Classification
Key Concepts3
In a nationwide case-control study in Taiwan, glaucoma patients with depressive symptoms had significantly higher age-adjusted Charlson comorbidity index (ACCI) scores (P < .0001) compared to glaucoma patients without depression.
In a nationwide case-control study in Taiwan, higher age-adjusted Charlson comorbidity index (ACCI) scores (P < .0001), cerebrovascular diseases (odds ratio [OR] = 1.324, 95 % confidence interval [CI] = 1.118-1.568), dementia (OR = 2.647, 95 % CI = 2.142-3.270), thyroid diseases (OR = 1.720, 95 % CI = 1.366-2.165), headaches (OR = 1.299, 95 % CI = 1.112-1.518), and current use of systemic β-blockers (OR = 1.782, 95 % CI = 1.538-2.065) and calcium channel blockers (OR = 1.396, 95 % CI, 1.197-1.629) were found to increase the risk of depression in glaucoma patients.
In a nationwide case-control study in Taiwan, current use (past 6 months) of any topical antiglaucoma medications was not associated with an increased risk for depression in glaucoma patients.
Related Articles5
Impact of neighborhood-level deprivation on glaucoma prevalence and treatment: A review of the literature.
Systematic ReviewSymptomatic Presbyopia may Develop Earlier in Patients With Glaucoma-A Cross-Sectional Retrospective Cohort Study.
Cross-Sectional StudyPatients' Acceptance of Glaucoma Therapy in Sub-Saharan Africa.
Cross-Sectional StudyLong-Term Effect of Systemic Comorbidity on Glaucoma Medication Adherence.
Cohort StudyThe Effect of Insurance Coverage Laws on Glaucoma Eyedrop Medication Usage.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.